WallStSmart

Amphastar P (AMPH)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 8934% more annual revenue ($67.38B vs $745.79M). AMPH leads profitability with a 13.3% profit margin vs 3.6%. AMPH appears more attractively valued with a PEG of 2.77. AMPH earns a higher WallStSmart Score of 65/100 (C+).

AMPH

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 6.0Quality: 7.0
Piotroski: 3/9Altman Z: 2.23

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMPHUndervalued (+28.3%)

Margin of Safety

+28.3%

Fair Value

$39.87

Current Price

$29.37

$10.50 discount

UndervaluedFair: $39.87Overvalued
MRKSignificantly Overvalued (-74.0%)

Margin of Safety

-74.0%

Fair Value

$84.93

Current Price

$144.52

$59.59 premium

UndervaluedFair: $84.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMPH3 strengths · Avg: 8.7/10
EPS GrowthGrowth
135.1%10/10

Earnings expanding 135.1% YoY

P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

Areas to Watch

AMPH3 concerns · Avg: 2.7/10
Market CapQuality
$1.22B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.772/10

Expensive relative to growth rate

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AMPH

The strongest argument for AMPH centers on EPS Growth, P/E Ratio, Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AMPH

The primary concerns for AMPH are Market Cap, Piotroski F-Score, PEG Ratio.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

AMPH carries more volatility with a beta of 0.94 — expect wider price swings.

AMPH is growing revenue faster at 8.2% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMPH scores higher overall (65/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphastar P

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?